All In Biotech

Drug Trial Radar · NCT05511922

PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

A Pharmacokinetic Subtrial in Adolescent Patients With Hereditary Angioedema Type I or II Participating in the KVD900-302 Trial

Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

11

Actual

Start

Oct 24, 2022

Primary completion

May 27, 2026

Study completion May 27, 2026

Sponsor

Lead sponsor
KalVista Pharmaceuticals, Ltd.Industry
Sponsor type
Industry
First posted
Aug 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 (sebetralstat) in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.

Conditions

  • Hereditary Angioedema

Interventions

  • KVD900 600 mgDrug

    KVD900 Tablet 600 mg (2 x 300 mg)

  • Drug: KVD900 300 mgDrug

    KVD900 Tablet 300 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics - CmaxTime frame: Up to 6 hours after IMP administration
  2. Pharmacokinetics - TmaxTime frame: Up to 6 hours after IMP administration
  3. Pharmacokinetics - AUCTime frame: Up to 6 hours after IMP administration

Locations

61 sites in 17 countries. Site status is shown where the registry gives one.

  • KalVista Investigative Site

    Scottsdale, Arizona

  • KalVista Investigative Site

    Little Rock, Arkansas

  • KalVista Investigative Site

    San Diego, California

  • KalVista Investigative Site

    San Diego, California

  • KalVista Investigative Site

    Santa Monica, California

  • KalVista Investigative Site

    Centennial, Colorado

  • KalVista Investigative Site

    Colorado Springs, Colorado

  • KalVista Investigative Site

    Evansville, Indiana

  • KalVista Investigative Site

    Overland Park, Kansas

  • KalVista Investigative Site

    Louisville, Kentucky

  • KalVista Investigative Site

    Chevy Chase, Maryland

  • KalVista Investigative Site

    Plymouth, Minnesota

  • KalVista Investigative Site

    St Louis, Missouri

  • KalVista Investigative Site

    Charlotte, North Carolina

  • KalVista Investigative Site

    Cincinnati, Ohio

  • KalVista Investigative Site

    Toledo, Ohio

  • Kalvista Investigative Site

    Hershey, Pennsylvania

  • KalVista Investigative Site

    Dallas, Texas

  • KalVista Investigative Site

    Layton, Utah

  • KalVista Investigative Site

    Spokane, Washington

  • KalVista Investigative Site

    Campbelltown, Australia

  • KalVista Investigative Site

    Vienna, Austria

  • KalVista Investigative Site

    Sofia, Bulgaria

  • KalVista Investigative Site

    Montreal, Canada

  • KalVista Investigative Site

    Grenoble, France

  • KalVista Investigative Site

    Lille, France

  • KalVista Investigative Site

    Paris, France

  • KalVista Investigative Site

    Berlin, Germany

  • KalVista Investigative Site

    Frankfurt, Germany

  • KalVista Investigative Site

    Mainz, Germany

  • KalVista Investigative Site

    Mörfelden-Walldorf, Germany

  • KalVista Investigative Site

    Athens, Greece

  • KalVista Investigative Site

    Athens, Greece

  • KalVista Investigative Site

    Haifa, Israel

  • KalVista Investigative Site

    Petach Tikvah, Israel

  • KalVista Investigative Site

    Ramat Gan, Israel

  • KalVista Investigative Site

    Tel Aviv, Israel

  • KalVista Investigative Site

    Chiba, Japan

  • KalVista Investigative Site

    Hiroshima, Japan

  • KalVista Investigative Site

    Kawagoe-shi, Japan

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.